In Hungary, the cost of lenalidomide-based therapy is covered only for relapsed multiple myeloma (MM) patients, therefore lenalidomide is typically used in the second-line either as part of a triplet with proteasome inhibitors or as a doublet. Lenalidomide-dexamethasone is a standard treatment approach for relapsed/refractory MM, and according to recent large randomized clinical trials (RCT, the standard arm of POLLUX, ASPIRE, TOURMALINE), the progression-free survival (PFS) is expected to be approximately 18 months. We surveyed ten Hungarian centers treating MM and collected data of 278 patients treated predominantly after 2016. The median age was 65 years, and patients were distributed roughly equally over the 3 international staging system groups, but patients with high risk cytogenetics were underrepresented. 15.8% of the patients reached complete response, 21.6% very good partial response, 40.6% partial response, 10.8% stable disease, and 2.5% progressed on treatment. The median PFS was unexpectedly long, 24 months, however only 9 months in those with high risk cytogenetics. We found interesting differences between centers regarding corticosteroid type (prednisolone, methylprednisolone or dexamethasone) and dosing, and also regarding the choice of anticoagulation, but the outcome of the various centers were not different. Although the higher equivalent steroid dose resulted in more complete responses, the median PFS of those having lower corticosteroid dose and methylprednisolone were not inferior compared to the ones with higher dose dexamethasone. On multivariate analysis high risk cytogenetics and the number of prior lines remained significant independent prognostic factors regarding PFS (p < 0.001 and p = 0.005). Our results show that in well-selected patients Lenalidomide-dexamethasone can be a very effective treatment with real-world results that may even outperform those reported in the recent RCTs. This real world information may be more valuable than outdated RCT data when treatment options are discussed with patients.
Background/Objectives: Despite therapeutic advances, managing relapsed/refractory multiple myeloma (RRMM) remains challenging. For patients with frailty, comorbidities, mobility limitations, or when treatment preference and drug accessibility are key considerations, the all-oral ixazomib–lenalidomide–dexamethasone (IRd) regimen offers a practical alternative. Methods: We performed a multicenter retrospective study of RRMM patients treated with IRd in Hungary between 1 January 2020 and 30 June 2025. Results: The median age at treatment initiation was 73.7 years. Treatment was initiated for clinical progression in 38.2%, biochemical progression in 53.3%, and for intolerance or toxicity of prior therapy in 8.6%. Median progression-free survival (PFS) was 18.7 months, and median overall survival (OS) was 34.7 months. Patients treated at biochemical progression had significantly longer PFS than those treated at clinical progression (24.3 vs. 15.6 months; p = 0.004), with additional benefit when IRd was initiated owing to intolerance or toxicity of previous therapy (p = 0.04). In the second-line setting, median PFS was 24.5 months, and median OS was not reached. Adverse events occurred in 68.3% of patients; dose reductions were required in 18.4%, and 21.6% discontinued treatment because of intolerance or toxicity. Most common toxicities were neutropenia (32.9%), thrombocytopenia (27.6%), diarrhoea (25%), peripheral neuropathy (25.3%), and infections (22.4%). Conclusions: IRd initiation at biochemical progression was associated with superior PFS compared with treatment at clinical progression. When compared with a recent Hungarian multicenter cohort treated with second-line daratumumab, lenalidomide, and dexamethasone, outcomes with IRd are not significantly inferior (36-month OS calculated from 2nd line treatment initiation: 65.5% for DRd vs. 60% in our cohort; p = 0.56). These real-world data support IRd as an effective, convenient, all-oral option for appropriately selected RRMM patients.
A myeloma megelőző állapotok, az MGUS és a smoldering myeloma (SMM) a népesség igen jelentős részét érintik, együttes előfordulásuk a 40 év feletti átlagpopulációban meghaladja a 3-4%-ot. Nagy jelentősége van tehát annak, hogy ebben a hatalmas, heterogén betegcsoportban meg tudjuk különböztetni azokat, akiknél az MGUS véletlen lelet, és irreleváns állapotuk szempontjából, illetve azokat, akik kiemelten fenyegetettek a myelomába történő progresszió által. A rendelkezésre álló biomarkerek (M protein-, és könnyűláncszintek, a termelt immunglobulin típusa, a csontvelői plazmasejtek aránya és citogenetikai eltérései) alapján határozhatjuk meg azon MGUS-betegeket, akiknél további vizsgálatok (csontrendszeri képalkotók, csontvelővizsgálat) és intenzív követés szükséges. SMM esetén mindenképpen szükséges a hematológiai gondozás. Újabb vizsgálatok szerint a SMM gyakorisága sokszorosan meghaladhatja a korábban becsült incidenciát (40 év felett néhány ezrelék lehet!). Bár több folyó klinikai vizsgálat igyekszik megoldást találni, sem MGUS, sem SMM esetén nem áll jelenleg rendelkezésünkre olyan terápiás lehetőség, amellyel a myelomába történő progresszió megállítható vagy visszafordítható lenne. Az érintettek gondozásakor ezért a minél pontosabb rizikóbecslés alapján történő követés az elsődleges, a progresszióval jelentkező visszafordíthatatlan szövődmények (veseelégtelenség, csonttörések, könnyűlánc amyloidosis) megelőzése céljából.